CDT1 is a Potential Therapeutic Target for the Progression of NAFLD to HCC and the Exacerbation of Cancer
Authors:
Top Cited Papers
Open Access
- 1 March 2025
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Genomics
- Vol. 26 (3) , 225-243
Abstract
Aims: This study aimed to identify potential therapeutic targets in the progression from non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC), with a focus on genes that could influence disease development and progression. Background: Hepatocellular carcinoma, significantly driven by non-alcoholic fatty liver disease, represents a major global health challenge due to late-stage diagnosis and limited treatment options. This study utilized bioinformatics to analyze data from GEO and TCGA, aiming to uncover molecular biomarkers that bridge NAFLD to HCC. Through identifying critical genes and pathways, our research seeks to advance early detection and develop targeted therapies, potentially improving prognosis and personalizing treatment for NAFLD-HCC patients. Objective: Identify key genes that differ between NAFLD and HCC; Analyze these genes to understand their roles in disease progression; Validate the functions of these genes in NAFLD to HCC transition. Methods: Initially, we identified a set of genes differentially expressed in both NAFLD and HCC using second-generation sequencing data from the GEO and TCGA databases. We then employed a Cox proportional hazards model and a Lasso regression model, applying machine learning techniques to the large sample data from TCGA. This approach was used to screen for key disease-related genes, and an external dataset was utilized for model validation. Additionally, pseudo-temporal sequencing analysis of single-cell sequencing data was performed to further examine the variations in these genes in NAFLD and HCC. Results: The machine learning analysis identified IGSF3, CENPW, CDT1, and CDC6 as key genes. Furthermore, constructing a machine learning model for CDT1 revealed it to be the most critical gene, with model validation yielding an ROC value greater than 0.80. The single-cell sequencing data analysis confirmed significant variations in the four predicted key genes between the NAFLD and HCC groups. Conclusion: Our study underscores the pivotal role of CDT1 in the progression from NAFLD to HCC. This finding opens new avenues for early diagnosis and targeted therapy of HCC, highlighting CDT1 as a potential therapeutic target.Keywords
Funding Information
- National Natural Science Foundation of China (81900404)
- Natural Science Foundation of Sichuan Province (24NSFSC2535)
This publication has 72 references indexed in Scilit:
- m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2022
- Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging StudiesClinical Gastroenterology and Hepatology, 2022
- Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinomaComputational and Structural Biotechnology Journal, 2022
- The impact of MCM6 on hepatocellular carcinoma in a Southern Chinese Zhuang populationBiomedicine & Pharmacotherapy, 2020
- Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cellsMolecular Biology Reports, 2020
- Cdc6 as a novel target in cancer: Oncogenic potential, senescence and subcellular localisationInternational Journal of Cancer, 2020
- Insulin Resistance and Genetic Risk Predict Liver‐Related Outcomes and Death in Nonalcoholic Fatty Liver DiseaseHepatology Communications, 2019
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- RNA‐Seq: A Method for Comprehensive Transcriptome AnalysisCurrent Protocols in Molecular Biology, 2010
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005